Creative Medical Technology Holdings Develops AI-Driven Diagnostic And Treatment Program For Biologic And Chemical Exposure
Portfolio Pulse from Benzinga Newsdesk
Creative Medical Technology Holdings (CELZ) has developed an AI-driven diagnostic and treatment program for biologic and chemical exposure.
July 24, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Creative Medical Technology Holdings (CELZ) has developed an AI-driven diagnostic and treatment program for biologic and chemical exposure.
The development of an AI-driven diagnostic and treatment program is a significant innovation for CELZ, likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100